FOXA1 mutations in prostate cancer cells are reported to reduce the number of AR binding sites but replaces AR function by increasing the activities of AR target genes (139) AR coactivators and FOXA1 are known to interact with AR by binding to numerous enhancers to increase AR signaling (77). Here, AR is linked to prostate carcinoma.